Opportunity?
Anthrayacline and Trastuzumab combo therapy has high incidence of cardiac events and thus never really taken off. If anthracycline cardiotoxicity is reduced then the combo might become relevant. Or, if Bisantrene also protects against Trastuzumab induced cardiotoxicity alone.
Cardioprotection thread, page-80
-
- There are more pages in this discussion • 841 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |